Early ravulizumab for recent-onset generalized myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests an early treatment with ravulizumab (a medication that blocks part of the immune system) for people who have recently developed moderate-to-severe generalized myasthenia gravis. The goal is to see if starting treatment early can improve symptoms and daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of generalized myasthenia gravis with anti-AChR antibodies.
- Your MG symptoms started within the last 3 years.
- Your MG is moderate to severe (MGFA class IIb, III, or IV).
- You cannot have been treated before with ravulizumab or similar C5 inhibitors.
- You must be vaccinated against meningitis (or take preventive antibiotics) at least 2 weeks before starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether ravulizumab, a medication that blocks part of the immune system, can improve muscle weakness and fatigue in people with generalized myasthenia gravis (gMG). The study focuses on Chinese adults who have moderate-to-severe MG symptoms despite current treatments.
This study is for people with generalized myasthenia gravis who are already on ravulizumab and a daily steroid. It aims to see if the steroid dose can be safely lowered over time.
This study follows patients with generalized myasthenia gravis (a condition where muscles weaken over time) who have specific antibodies and are being treated with rozanolixizumab, a medication that helps reduce symptom severity. Researchers will monitor how symptoms change in real-world settings.
This trial tests an investigational drug called SHR-2173, given as an injection, for people with generalized myasthenia gravis. It aims to see if the drug can improve muscle strength and daily function.
This study tests a new drug called gefurulimab in children and teens with generalized myasthenia gravis (a disease that causes muscle weakness). It looks at how safe and effective the drug is, and how it works in the body.
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
Hear when a new Generalized Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.